patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_965617 | REC_0006701 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 2 | 66 | female | 1 | 25 | 4.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.4 | false | MSS | 2026-03-15T05:35:58.498080+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670801 | REC_0006702 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 14.9 | 79 | female | 2 | 7 | 3.7 | 4 | sotorasib 960 mg daily | 8.9 | false | MSI-H | 2026-03-15T05:35:58.498312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947011 | REC_0006703 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 12.6 | 55 | female | 1 | 22 | 6.4 | 2 | sotorasib 960 mg daily | 15.4 | true | MSS | 2026-03-15T05:35:58.498548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229529 | REC_0006704 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.5 | 71 | male | 2 | 17 | 3.9 | 5 | alectinib 600 mg BID | 12.7 | false | MSI-H | 2026-03-15T05:35:58.498785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387506 | REC_0006705 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 6.9 | 66 | female | 0 | 11 | 5 | 2 | alectinib 600 mg BID | 9.6 | false | MSS | 2026-03-15T05:35:58.499013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420502 | REC_0006706 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 7.9 | 64 | male | 0 | 8 | 5 | 1 | sotorasib 960 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:58.499243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571828 | REC_0006707 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 35 | 12.3 | 74 | female | 0 | 24 | 5.5 | 3 | entrectinib 600 mg daily | 24.9 | false | MSS | 2026-03-15T05:35:58.499473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115929 | REC_0006708 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 15.9 | 69 | male | 0 | 9 | 5.3 | 6 | entrectinib 600 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:58.499709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408063 | REC_0006709 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 5.2 | 83 | female | 1 | 33 | 6.3 | 1 | pembrolizumab 200 mg q3w | 18.4 | false | MSS | 2026-03-15T05:35:58.499990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775508 | REC_0006710 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 6.3 | 69 | male | 1 | 22 | 7 | 6 | alectinib 600 mg BID | 14 | false | MSS | 2026-03-15T05:35:58.500254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970235 | REC_0006711 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 6.5 | 73 | female | 3 | 12 | 4.9 | 4 | entrectinib 600 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:58.500488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341300 | REC_0006712 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.7 | 66 | male | 0 | 25 | 4.5 | 10 | sotorasib 960 mg daily | 5.3 | true | MSI-H | 2026-03-15T05:35:58.500727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978220 | REC_0006713 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 11.1 | 69 | female | 1 | 8 | 4.6 | 1 | osimertinib 80 mg daily | 8 | false | MSI-H | 2026-03-15T05:35:58.500962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756104 | REC_0006714 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 10.1 | 71 | female | 0 | 50 | 6.9 | 2 | pembrolizumab 200 mg q3w | 18.4 | false | MSI-H | 2026-03-15T05:35:58.501198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593789 | REC_0006715 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 18.4 | 74 | female | 1 | 13 | 6.3 | 1 | sotorasib 960 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:58.501436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485000 | REC_0006716 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 30 | 13.4 | 77 | female | 1 | 6 | 6.5 | 0 | osimertinib 80 mg daily | 51.3 | true | MSI-H | 2026-03-15T05:35:58.501666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841899 | REC_0006717 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 8.4 | 55 | female | 0 | 15 | 4.6 | 1 | osimertinib 80 mg daily | 21.7 | false | MSS | 2026-03-15T05:35:58.501899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779475 | REC_0006718 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 6.6 | 68 | female | 1 | 3 | 5.3 | 2 | pembrolizumab 200 mg q3w | 25.7 | false | MSS | 2026-03-15T05:35:58.502127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227031 | REC_0006719 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 4.8 | 69 | female | 1 | 10 | 4 | 1 | pembrolizumab 200 mg q3w | 13.9 | true | MSS | 2026-03-15T05:35:58.502357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589784 | REC_0006720 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 16.6 | 62 | female | 0 | 17 | 6.6 | 5 | osimertinib 80 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:58.502590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397862 | REC_0006721 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 10.1 | 74 | female | 1 | 15 | 5.7 | 5 | alectinib 600 mg BID | 10 | true | MSS | 2026-03-15T05:35:58.502823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176243 | REC_0006722 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 8.5 | 67 | female | 0 | 14 | 5.9 | 7 | osimertinib 80 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:58.503107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456490 | REC_0006723 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 14.8 | 52 | female | 0 | 19 | 6.4 | 5 | osimertinib 80 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:58.503346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173988 | REC_0006724 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 12.3 | 85 | female | 1 | 18 | 7 | 2 | entrectinib 600 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:58.503585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148202 | REC_0006725 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 8.1 | 81 | male | 0 | 24 | 6 | 5 | alectinib 600 mg BID | 7.6 | false | MSS | 2026-03-15T05:35:58.503818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137026 | REC_0006726 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 5.5 | 55 | female | 1 | 24 | 6 | 0 | osimertinib 80 mg daily | 43 | false | MSS | 2026-03-15T05:35:58.504048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941898 | REC_0006727 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 15.8 | 65 | male | 0 | 15 | 6 | 6 | osimertinib 80 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:58.504311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532731 | REC_0006728 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 34 | 7.3 | 64 | male | 1 | 47 | 6.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 29.9 | false | MSS | 2026-03-15T05:35:58.504545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500722 | REC_0006729 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.8 | 60 | female | 1 | 21 | 7 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.504783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574215 | REC_0006730 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.2 | 75 | male | 2 | 14 | 6.6 | 5 | sotorasib 960 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:58.505020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870851 | REC_0006731 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.9 | 72 | female | 1 | 22 | 3.7 | 6 | alectinib 600 mg BID | 11 | false | MSI-H | 2026-03-15T05:35:58.505258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576525 | REC_0006732 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 14 | 66 | female | 1 | 11 | 5.3 | 1 | sotorasib 960 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:58.505494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810784 | REC_0006733 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 14.5 | 64 | male | 1 | 8 | 6.1 | 2 | alectinib 600 mg BID | 19.5 | false | MSI-H | 2026-03-15T05:35:58.505730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185541 | REC_0006734 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.7 | 72 | female | 0 | 65 | 4.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.6 | true | MSS | 2026-03-15T05:35:58.505966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431262 | REC_0006735 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 13.7 | 63 | male | 1 | 20 | 5.6 | 7 | entrectinib 600 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:58.506262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131246 | REC_0006736 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 10 | 61 | female | 1 | 0 | 5.4 | 6 | sotorasib 960 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:35:58.506500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997797 | REC_0006737 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12.3 | 63 | male | 0 | 28 | 5 | 7 | osimertinib 80 mg daily | 20.3 | false | MSS | 2026-03-15T05:35:58.506735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388206 | REC_0006738 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 14.4 | 58 | female | 0 | 14 | 5.4 | 2 | osimertinib 80 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:35:58.506972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470496 | REC_0006739 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.4 | 65 | male | 0 | 15 | 6.4 | 6 | pembrolizumab 200 mg q3w | 8.9 | true | MSS | 2026-03-15T05:35:58.507204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760462 | REC_0006740 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 10.8 | 62 | male | 1 | 5 | 5.6 | 6 | sotorasib 960 mg daily | 22.5 | false | MSI-H | 2026-03-15T05:35:58.507439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102295 | REC_0006741 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 14 | 76 | female | 1 | 14 | 6.5 | 6 | sotorasib 960 mg daily | 16.4 | false | MSI-H | 2026-03-15T05:35:58.507675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606825 | REC_0006742 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 7.7 | 73 | female | 2 | 48 | 5.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.5 | true | MSS | 2026-03-15T05:35:58.507906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667986 | REC_0006743 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 9.1 | 58 | male | 1 | 14 | 4.6 | 2 | pembrolizumab 200 mg q3w | 6.9 | true | MSS | 2026-03-15T05:35:58.508194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237506 | REC_0006744 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 13.3 | 63 | female | 0 | 18 | 4 | 2 | entrectinib 600 mg daily | 28.1 | false | MSS | 2026-03-15T05:35:58.508437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300018 | REC_0006745 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16.3 | 69 | female | 0 | 18 | 6 | 5 | alectinib 600 mg BID | 13 | false | MSI-H | 2026-03-15T05:35:58.508671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713328 | REC_0006746 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 4 | 70 | female | 2 | 37 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:35:58.508914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_595034 | REC_0006747 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 15.8 | 66 | female | 0 | 11 | 3.6 | 1 | osimertinib 80 mg daily | 16.3 | true | MSI-H | 2026-03-15T05:35:58.509148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162359 | REC_0006748 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 14.4 | 69 | female | 1 | 21 | 6.6 | 6 | pembrolizumab 200 mg q3w | 16.1 | true | MSS | 2026-03-15T05:35:58.509460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937797 | REC_0006749 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 11.5 | 80 | female | 2 | 21 | 3.2 | 1 | entrectinib 600 mg daily | 16.1 | false | MSS | 2026-03-15T05:35:58.509698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852837 | REC_0006750 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 17.1 | 73 | female | 1 | 12 | 7.1 | 8 | alectinib 600 mg BID | 9.7 | false | MSI-H | 2026-03-15T05:35:58.509936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204112 | REC_0006751 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 3.8 | 73 | female | 1 | 16 | 4.7 | 6 | pembrolizumab 200 mg q3w | 12.5 | false | MSS | 2026-03-15T05:35:58.510165+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708128 | REC_0006752 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 33 | 5.5 | 62 | female | 1 | 88 | 5.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 8 | true | MSS | 2026-03-15T05:35:58.510398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267677 | REC_0006753 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 7.4 | 73 | female | 0 | 19 | 5.7 | 1 | pembrolizumab 200 mg q3w | 18.2 | true | MSS | 2026-03-15T05:35:58.510627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176397 | REC_0006754 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 14.9 | 63 | female | 1 | 19 | 7.4 | 4 | alectinib 600 mg BID | 17.8 | true | MSS | 2026-03-15T05:35:58.510862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688623 | REC_0006755 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.5 | 60 | male | 0 | 7 | 3.8 | 6 | sotorasib 960 mg daily | 8.8 | true | MSI-H | 2026-03-15T05:35:58.511095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719297 | REC_0006756 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 14.4 | 62 | male | 0 | 19 | 4.6 | 2 | alectinib 600 mg BID | 15.1 | true | MSI-H | 2026-03-15T05:35:58.511330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218225 | REC_0006757 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 2.2 | 63 | male | 0 | 23 | 5.6 | 6 | sotorasib 960 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:58.511562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304100 | REC_0006758 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 6.8 | 73 | male | 2 | 11 | 4.8 | 1 | osimertinib 80 mg daily | 21.9 | false | MSS | 2026-03-15T05:35:58.511793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461587 | REC_0006759 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 7.2 | 62 | female | 1 | 16 | 4.8 | 9 | entrectinib 600 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:58.512028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731533 | REC_0006760 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 11.2 | 66 | female | 0 | 11 | 6.1 | 6 | entrectinib 600 mg daily | 10 | true | MSS | 2026-03-15T05:35:58.512291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854304 | REC_0006761 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 11.8 | 68 | female | 1 | 16 | 6.7 | 1 | entrectinib 600 mg daily | 27.8 | true | MSI-H | 2026-03-15T05:35:58.512580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831716 | REC_0006762 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 6 | 70 | female | 2 | 56 | 4.1 | 5 | pembrolizumab 200 mg q3w | 6.7 | false | MSS | 2026-03-15T05:35:58.512813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767658 | REC_0006763 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 7.7 | 74 | female | 4 | 12 | 5.5 | 2 | osimertinib 80 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:58.513048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857658 | REC_0006764 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 6.2 | 43 | female | 0 | 25 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.5 | false | MSS | 2026-03-15T05:35:58.513280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470885 | REC_0006765 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 13.3 | 63 | female | 0 | 13 | 7 | 7 | entrectinib 600 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:58.513518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276485 | REC_0006766 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.4 | 75 | female | 2 | 71 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.2 | false | MSS | 2026-03-15T05:35:58.513750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323098 | REC_0006767 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.1 | 77 | female | 2 | 11 | 5.7 | 6 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:35:58.513984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766242 | REC_0006768 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 10.8 | 61 | male | 0 | 0 | 5.9 | 5 | alectinib 600 mg BID | 5.4 | false | MSS | 2026-03-15T05:35:58.514217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559717 | REC_0006769 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 8.7 | 55 | female | 1 | 7 | 5.2 | 3 | alectinib 600 mg BID | 12.7 | true | MSS | 2026-03-15T05:35:58.514445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410023 | REC_0006770 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 5.8 | 66 | female | 0 | 23 | 4.4 | 1 | entrectinib 600 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:58.514671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506550 | REC_0006771 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 11.4 | 61 | female | 0 | 13 | 6.3 | 6 | osimertinib 80 mg daily | 15.5 | true | MSI-H | 2026-03-15T05:35:58.514907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426831 | REC_0006772 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 10.1 | 74 | female | 2 | 13 | 4.7 | 1 | pembrolizumab 200 mg q3w | 18.5 | false | MSI-H | 2026-03-15T05:35:58.515138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375257 | REC_0006773 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 12.6 | 68 | male | 0 | 13 | 6 | 2 | sotorasib 960 mg daily | 24.6 | false | MSS | 2026-03-15T05:35:58.515374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977627 | REC_0006774 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 12.5 | 55 | male | 0 | 31 | 3.8 | 2 | entrectinib 600 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:35:58.515667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694060 | REC_0006775 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 15.6 | 65 | male | 1 | 15 | 6.8 | 5 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:58.515909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200254 | REC_0006776 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 6.3 | 73 | female | 2 | 16 | 2.7 | 2 | pembrolizumab 200 mg q3w | 12.1 | false | MSS | 2026-03-15T05:35:58.516172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482061 | REC_0006777 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 13.6 | 68 | female | 0 | 10 | 10 | 7 | alectinib 600 mg BID | 12.8 | false | MSI-H | 2026-03-15T05:35:58.516412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424061 | REC_0006778 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 33 | 16.2 | 75 | male | 1 | 17 | 4 | 0 | osimertinib 80 mg daily | 66.1 | true | MSS | 2026-03-15T05:35:58.516650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487429 | REC_0006779 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 9.4 | 70 | female | 2 | 14 | 5.9 | 4 | entrectinib 600 mg daily | 8.8 | true | MSS | 2026-03-15T05:35:58.516882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900605 | REC_0006780 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.4 | 75 | female | 2 | 11 | 6.6 | 4 | osimertinib 80 mg daily | 11 | true | MSI-H | 2026-03-15T05:35:58.517112+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709952 | REC_0006781 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.1 | 69 | male | 1 | 12 | 5.2 | 6 | pembrolizumab 200 mg q3w | 11.8 | true | MSS | 2026-03-15T05:35:58.517345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632491 | REC_0006782 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 8.5 | 69 | female | 0 | 10 | 2.8 | 1 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:58.517573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202923 | REC_0006783 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 18.4 | 66 | female | 0 | 9 | 4.8 | 5 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:35:58.517812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639939 | REC_0006784 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 8 | 55 | male | 0 | 10 | 5.9 | 0 | osimertinib 80 mg daily | 20.3 | false | MSS | 2026-03-15T05:35:58.518042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360476 | REC_0006785 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 10.8 | 62 | female | 0 | 16 | 5.4 | 6 | alectinib 600 mg BID | 8.4 | true | MSI-H | 2026-03-15T05:35:58.518276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361363 | REC_0006786 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 15.9 | 71 | male | 2 | 21 | 6.8 | 5 | sotorasib 960 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:58.518510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183978 | REC_0006787 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 17.8 | 65 | female | 1 | 18 | 5 | 5 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:58.518802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261177 | REC_0006788 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.1 | 65 | male | 1 | 83 | 7.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.7 | true | MSS | 2026-03-15T05:35:58.519036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246658 | REC_0006789 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 15.6 | 57 | male | 1 | 7 | 4.7 | 5 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:58.519274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735567 | REC_0006790 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 14.5 | 75 | female | 2 | 11 | 3.6 | 5 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:58.519508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655191 | REC_0006791 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 15 | 65 | female | 0 | 6 | 5.4 | 1 | alectinib 600 mg BID | 15.8 | true | MSS | 2026-03-15T05:35:58.519744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489254 | REC_0006792 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 9.7 | 63 | male | 1 | 11 | 9.5 | 5 | alectinib 600 mg BID | 9 | true | MSS | 2026-03-15T05:35:58.519973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166221 | REC_0006793 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 12.3 | 60 | male | 1 | 22 | 6.5 | 6 | osimertinib 80 mg daily | 18.1 | true | MSS | 2026-03-15T05:35:58.520339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318771 | REC_0006794 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 13.4 | 82 | male | 2 | 14 | 6.4 | 7 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.520603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461924 | REC_0006795 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 16.4 | 76 | female | 1 | 6 | 5 | 2 | sotorasib 960 mg daily | 17.9 | false | MSS | 2026-03-15T05:35:58.520840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326065 | REC_0006796 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 9.7 | 65 | female | 1 | 9 | 7.8 | 7 | osimertinib 80 mg daily | 4.9 | true | MSS | 2026-03-15T05:35:58.521071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334365 | REC_0006797 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 19 | 7.2 | 67 | female | 1 | 20 | 4.9 | 0 | sotorasib 960 mg daily | 17.9 | true | MSS | 2026-03-15T05:35:58.521299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434470 | REC_0006798 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 15.7 | 75 | female | 1 | 21 | 4.8 | 3 | osimertinib 80 mg daily | 18.3 | false | MSS | 2026-03-15T05:35:58.521529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233847 | REC_0006799 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8 | 74 | female | 1 | 61 | 4.4 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.8 | true | MSS | 2026-03-15T05:35:58.521759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708796 | REC_0006800 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.4 | 75 | female | 2 | 41 | 6.2 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.9 | true | MSS | 2026-03-15T05:35:58.522047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.